Last update June 27, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Meprobamate is also known as
Meprobamate in other languages or writings:
Main tradenames from several countries containing Meprobamate in its composition:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by El Parto Es Nuestro of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Meprobamate is a carbamate with hypnotic, sedative, and muscle relaxant properties. It is an active metabolite of Carisoprodol. It is used in anxiety disorders, insomnia, and spastic and painful musculoskeletal disorders. Oral administration in 3 to 4 daily doses.
It is excreted in breast milk (Sachs 2013, Bailey 2002, Wilson 1980), but in clinically insignificant amounts, and no problem has been observed in an infant whose mother was taking it. (Nordang 2001)
Meprobamate has a powerful sedative effect. It has been withdrawn from the market in numerous countries due to its poor risk/benefit ratio. (EMA 2012)
It is recommended to check for sedation and/or lack of appetite in infants (Sachs 2013). Bed-sharing (co-sleeping) with the baby is not recommended if this drug are used. (ABM 2020 y 2008, UNICEF 2018, 2017, 2014 y 2013, Landa 2012, UNICEF 2006)
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity.